Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy - Novo Nordisk ( NYSE:NVO )
At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S NVO shared an abstract with data from the company's next-generation weight loss candidate, amycretin. Earlier today, Novo Nordisk announced that its weight-loss drug liraglutide is safe and effective for ...
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
17 %
|
|
SSTK
|
Neutral
|
9 %
|
|
NVO
|
Somewhat Bullish
|
41 %
|
